ArticleFrontiers in immunology2022

Study of epirubicin sustained-release chemoablation in tumor suppression and tumor microenvironment remodeling.

Liangliang Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.